RevOpsis, Kemwell Biopharma enter strategic partnership to expedite development of biologics for treatment of nAMD


According to the companies, the partnership will accelerate the development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-related macular degeneration.

(Image Credit: AdobeStock/Donson/

(Image Credit: AdobeStock/Donson/

RevOpsis Therapeutics and Kemwell Biopharma announced a strategic manufacturing partnership.

According to the companies, the goal of this collaboration is to accelerate the development of RevOpsis' lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).

Under terms of the agreement, Kemwell will manufacture RO-104, a novel tri-specific biologic designed to target the 3 dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) for treating nAMD. The ability of RO-104 to bind these 3 validated targets simultaneously positions it as a fully human monotherapy biologic.1

Ram Bhandari, MD, co-founder and interim CEO of RevOpsis, noted in a news release the company’s collaboration with Kemwell is a step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics.

“Kemwell's exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently,” Bhandari said in the news release. “This collaboration aligns with our mission to develop groundbreaking treatments expeditiously, and bring our innovation to patients worldwide."

Anurag Bagaria, CEO of Kemwell Biopharma, said the company is pleased to collaborate with RevOpsis to manufacture and commercialize RO-104.

“Our expertise in complex protein manufacturing, coupled with RevOpsis' innovative therapeutic approaches, holds great promise for advancing the treatment of retinal vascular diseases,” Bagaria said in the news release. “This strategic partnership underscores our commitment to delivering high-quality biologics for patients in need."

Moreover, the collaboration will give RevOpsis a biologics development solution to transition from pre-clinical activities to first-in-human clinical trials, expediting the development of RO-104 and the broader platform. By integrating RevOpsis' next-generation plug-and-play multispecific biologics platform with Kemwell's biologics development and manufacturing knowledge, the collaboration aims to accelerate therapeutic discovery to IND submission timelines.

The collaboration also will link preclinical efforts, process development, and clinical manufacturing, reducing the complexity and timelines of managing early GMP manufacturing process.

Leveraging RevOPsis’ Rev-Mod platform, RO-104 is the company’s current lead candidate. The company said the candidate is engineered as a first-in-class fully human modular tri-specific biologic designed to address all 3 clinically validated dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in retinal vascular disease progression, including neovascular age-related macular degeneration (nAMD).1

The Rev-Mod Platform employs a modular 'plug-and-play' approach to streamline and expedite the efficient discovery and development of multispecific biologics targeting a wide spectrum of chronic, prevalent, large diseases, that are the leading causes of death and disability worldwide.

  1. RevOpsis. RevOpsis and Kemwell Biopharma Enter into Strategic Manufacturing Partnership to Expedite Development of Novel Multispecific Biologics. Accessed June 18, 2024.
Recent Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Video 5 - "Evolving Role of Steroids and Laser In DME"
Video 3 - "Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent"
Video 2 - "A Case of Neovascular AMD with Persistent Subretinal Fluid"
Video 1 - "A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment"
© 2024 MJH Life Sciences

All rights reserved.